Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer
{{output}}
Lung cancer is one of the most common malignant cancers in most countries, and non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Checkpoint inhibitor immunotherapy is the preferred therapy for metastatic NSCLC patients who... ...
